Role of vasopressin antagonists in the management of acute decompensated heart failure.
Vasopressin antagonists are a class of neurohormonal antagonists with applications in both the short-term and long-term management of patients with acute decompensated heart failure (ADHF). The pharmacologic effects of vasopressin antagonists include changes in fluid balance and hemodynamics that may improve symptoms and outcomes in patients hospitalized with ADHF. With chronic therapy, vasopressin antagonists offer the potential to improve outcomes through a variety of mechanisms, including more effective treatment of congestion, preservation or improvement of renal function, or a reduction in the use of concomitant loop diuretic therapy. Several vasopressin antagonists are currently in advanced clinical trials for the treatment of ADHF, chronic stable heart failure, and hyponatremia.
Orlandi
Cesare
C
Department of Clinical Development, Otsuka Maryland Research Institute, Inc., 2440 Research Boulevard, Rockville, MD 20850, USA. cesareo@otsuka.com
Zimmer
Christopher A
CA
Gheorghiade
Mihai
M
D000208:Acute Disease; D065092:Antidiuretic Hormone Receptor Antagonists; D001381:Azepines / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D001552:Benzazepines / Q000627:therapeutic use*; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006801:Humans; D011758:Pyrroles; D013318:Stroke Volume / Q000187:drug effects; D000077602:Tolvaptan; D016896:Treatment Outcome; D014661:Vasoconstriction / Q000187:drug effects; D014667:Vasopressins / Q000037:antagonists & inhibitors* / Q000097:blood; D001569:Benzodiazepines
D065092:Antidiuretic Hormone Receptor Antagonists; D001381:Azepines; D001549:Benzamides; D001552:Benzazepines; D011758:Pyrroles; D000077602:Tolvaptan; D014667:Vasopressins; C409452:lixivaptan; D001569:Benzodiazepines